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Abstract—Warfarin for anticoagulation therapy is used by 
patients with specific cardiovascular diseases to control the 
ability of blood clotting. Traditional ways for self-management 
of the therapy are based on paper forms and procedures. This 
paper presents an algorithm developed for the smartphone 
application “Warfarin Guide”, which is a computer-assisted 
decision-support system used to help patients with self- 
management of their anticoagulation therapy related to 
International Normalized Ratio (INR) values. The algorithm 
was based on clinical guidelines for Warfarin therapy and it was 
adapted for the software application to address challenges with 
regular INR checks and adjustments for temporary 
fluctuations. An evaluation study with 14 participants showed 
that the patients evaluated the Warfarin Guide as useful for self-
management of anticoagulation therapy, even though some 
issues could be improved. 
Keywords—international normalized ratio, algorithms, 
computer-assisted therapy, medical informatics, eHealth 
I. INTRODUCTION 
The medication Warfarin is prescribed to patients with 
specific cardiovascular diseases, such as venous 
thromboembolic disorders, mechanical heart valves, and high-
risk groups with atrial fibrillation as a life-long 
anticoagulation therapy with the aim to control the ability of 
blood clotting and prevent thromboembolic complications [1].  
Measurements and monitoring of the International 
Normalized Ratio (INR) value are used to guide the Warfarin 
dosing and the intensity of the anticoagulant therapy [2][3]. 
Each patient is recommended a management strategy based on 
the case history with an individual therapeutic range of the 
INR value. A patient with a low INR has a risk of increased 
blood clotting and a high INR value indicates an increased risk 
of bleeding. Patients with increased blood clotting are exposed 
to a risk of life-threatening conditions such as cerebral 
infarction or pulmonary embolism. The individual INR values 
can be influenced by food intake with vitamin K-rich 
vegetables (i.e. broccoli and spinach) [4], and alcohol 
consumption [5], but illness, stress and physical exercise may 
also impact [6]. Patients using anticoagulation therapy can in 
some cases self-monitor the INR values [7] by a portable 
coagulometer device that samples whole blood obtained by a 
finger prick [8]. Fluctuations outside the therapeutic INR 
range have been reported in previous studies [9]. These 
unexpected fluctuations challenge the reliability of regular 
checks of INR values and the decision-making about 
anticoagulant medication dose adjustments based on the 
measured values. This brings to light practical challenges 
regarding regular checks of the INR values measured at home 
and decision-making about Warfarin dosing adjustments.  
In this context, the project Smartphone Warfarin Guide 
aimed to develop a software application for self-management 
of anticoagulation therapy to be used in smartphone or tablet 
devices. A decision-support algorithm for calculation and 
recommendation of medication was developed based on the 
Norwegian national clinical guidelines for Warfarin therapy 
[10]. This paper reports from the medication calculation 
algorithm development made in an early project phase.  
The following research question was addressed:  
What are the benefits and constraints of using a decision-
support algorithm in a software application for self-
management of anticoagulation therapy with Warfarin? 
II. METHODOLOGY 
A user-centred design approach was used for the 
development in the Smartphone Warfarin Guide project [11]. 
The development was conducted in four phases: 1) co-creation 
design workshops, 2) iterative development were the 
algorithm was extracted from the clinical guidelines and 
implemented to the software application, 3) usability 
evaluations in laboratory with anticoagulation therapy patients 
[12] and 4) long-term evaluation through a field test with 14 
anticoagulation therapy patients using the smartphone 
application at home during several months . The research team 
in the project had a multi-disciplinary background within 
health informatics, computer science and medicine. The 
technical development was made by three master students in 
information and communication technology, under 
supervision by members of the research team. The Norwegian 
Centre for Research Data approved the study, with project 




A. The Software Application 
Today, patients in Norway that are capable of self-
management of anticoagulation therapy manually follow the 
Noklus clinical guidelines for Warfarin dosage [10]. They 
have to measure their INR value weekly and keep track of it, 
remember when to measure the next time, calculate their 
current weekly medication dosage, and perform calculations 
of potentially required adjustments to the weekly dosage. In 
addition, the patients have to remember to take the appropriate 
dosage on a daily basis. 
The developed software application for smartphones or 
tablet-PC devices instructs and informs those patients about 
required INR measurements, medication dosage and timely 
medication intake, see Fig. 1. The application allows for more 
frequent INR measurements and corresponding adaptation of 
the daily Warfarin dosage. It removes the need to follow any 
complex instructions and calculations by the patient, and 
stores required data as INR values and current medication 
dosage. Moreover, by transmitting and storing those personal 
health data to a secure telehealth service for remote 
monitoring in a health information management 
infrastructure. The latest data are made available to authorised 
medical professionals for follow-up and support if needed, 
and for research and other clinical purposes.  
 
Fig. 1. The start screen of the software application. 
After installing the application in a device, a first-time-
configuration has to be carried out. The user must enter a code 
provided by a medical professional. With that code, the newly 
created user profile of the software application is linked to the 
individual patient profile in the telehealth service in the health 
information management infrastructure. As part of that user 
profile configuration, the INR-range is set to either “2.0-3.0” 
or to “2.5-3.5”, the patient’s initial medication dosage is set, 
and the secure data communication with the telehealth service 
is configured. 
After successful configuration, the main user interfaces of 
the application, include the following visible and functional 
elements (see Fig. 2 for examples): 
1. Patient’s latest dosage status. 
2. Patient’s most recent INR measurement. 
3. Due date for next INR measurement. 
4. Button to register new INR measurement. 
5. Button to access past “history” of measurements and 
medication dosages. 
6. “Help” button to gain access to application’s 
documentation. 
7. “Settings” button to gain access to settings and 
configuration of application. 
     
Fig. 2. The last measurement and today’s recommended dosage (left),  
the recommended dosage for a whole week (middle), and duration the INR 
value has been within the therapeutic range (green segment on right). 
B. The Medication Calculation Algorithm 
The Noklus clinical guidelines is a description for manual 
adjustments of the weekly Warfarin medication dosage by the 
patients, with the help of a portable INR measurement device. 
The following changes have been made for the medication 
calculation algorithm in the software application compared to 
the original guidelines: 
   
• A low INR value (0.0-1.6 or 0.0-1.9) used to have a 
choice whether or not to increase the weekly dose 
(low-molecular weight heparin injection should also 
be considered if INR <1.5). In the software application 
it is increased only if the last INR measurement was 
low. 
• “Take an extra daily dose divided into 1-2 days” is 
“take one extra daily dose today” in the software 
application. 
• If the answer to the question “Have you been sick, 
started on a new drug or been on holiday overseas” is 
“Yes”, the patient should do a measurement after 3-4 
days and that has been changed to 3 days. 
A flow chart of the resulting medication calculation 
algorithm including the changes and adaptations made for the 
software application is shown in Figure 3. This algorithm is 
used by the application every time a user is prompted to do a 
new measurement from the home screen. 
The INR ranges displayed under the label “INR 2.5” is for 
users with the therapeutic range “2.0-3.0”. The INR ranges 
displayed under the label “INR 3.0” is for users with the 
therapeutic range “2.5-3.5”. That means that if two users with 
different therapeutic ranges measured the same INR values, it 
is not certain they would trigger the same logic. E.g. if “INR 
2.5” users measure 2.0, it leads to no changes; if “INR 3.0” 
users measure 2.0, pills need to be added to the weekly dosage. 
C. The Field Test 
A field test for long-term evaluation of the smartphone 
application and the medication calculation algorithm was run 
with 14 participants, that all were anticoagulation therapy 
patients recruited from a local hospital. They used the 
smartphone application at home for four months. After two 
months they were requested to fill in a questionnaire on user 
experience regarding the design and functionality. After four 
months, there was a meeting was organized at the hospital for 
evaluation of the long-term experiences. 
 
 
Fig. 3. Flowchart of the medication calculation algorithm with changes to adapt for the software application.
The paper-based clinical guidelines were used in 
conjunction with the smartphone application to identify 
inconsistencies. The design suggestions from the field test 
targeted adaption for all types of smartphones as the 
application was only compatible with Android devices. A 
function for manual change of the measurement’s day was 
suggested and also transfer of the data to a personal computer 
for backup. During the field test, two discrepancies were 
found between the recommended week dose of the 
smartphone application compared to the clinical guidelines. 
IV. DISCUSSION AND CONCLUSION 
This paper has presented the medication calculation 
algorithm development for self-management of INR 
measurements and Warfarin dosing, that was implemented in 
the Smartphone application Warfarin Guide. With this 
application the manual process of medication determination 
based on a printed tabular guideline has been transformed into 
an application-based workflow.  
The field test with the anticoagulation therapy patients 
confirmed advantages of the application for the management 
of INR measurement dates, the information about the current 
daily and weekly medication dose, required temporary 
adjustments, as well as a log of previous INR values and taken 
medication doses.  
The algorithm allowed the adaptation of the medication 
dose to a continuous time-series of INR measurements, but it 
faced the challenge that the recommended daily dose (i.e. the 
total number of tablets in the weekly dose divided on seven 
days) can require the division of tablets. As solution, the 
algorithm rounded the dose to the nearest half tablet. This can 
explain some inconsistencies between the dosage 
recommended by the Noklus clinical guidelines and the 
dosage recommended from the smartphone application based 
 
 
on the algorithm. Further testing and validation of the 
algorithm under clinical supervision according to regulations 
for medical software [14] is required.  
The study carried out so far had some limitations, such as 
the limited number of participants included in the field trial 
for testing the medication calculation algorithm. Nevertheless, 
the study included real patients using anticoagulation therapy 
and they had a background that meaningfully represented the 
target end-user group. Future work would include 
implementation of Bluetooth transmission from the 
measurements’ device to the smartphone application to reduce 
the potential for errors due to the manual transfer of INR 
measurement results. Further, a randomised controlled trial 
(RCT) is under preparation, where a comparison between 
using the standardised paper-based clinical guidelines and the 
smartphone application for data-driven decision support will 
be made. The patients’ trust in the technology would also be 
an important topic to study further. 
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